Back to results
US 2026/0248925 A1Published application
Polypeptide pharmaceuticals
AssigneeMederis Diabetes LLC
InventorJohn J. Nestor
Life of this patent
Estimating the term…
Abstract
Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
Claims23
A peptide product comprising a surfactant X, covalently attached to a GLP-1 receptor (GLP1R) and/or glucagon receptor (GCGR) binding peptide, the peptide product comprising:
- wherein X is
- wherein
- A is a hydrophobic group comprising a C1-C30 alkyl chain;
- and
- B is a hydrophilic saccharide group covalently attached to the peptide via a linker amino acid U, wherein U is a natural or unnatural amino acid.
2 more elements
(canceled)
20-37. (canceled)
(canceled)
Dependencies are inferred from the claim text.